Biocept Comments on Updated Consensus Medical Guidelines Recommending Liquid Biopsy for Profiling of Tumor Biomarkers to Assist with the Treatment of Patients with Lung Cancer
The evidence-based guidelines were developed in collaboration by the
"These leading medical associations clearly see that liquid biopsy can be critical for obtaining actionable molecular information to improve treatment outcomes of patients diagnosed with lung cancer," said
Key guideline updates with regard to the use of liquid biopsy include the following:
- Recommendation 16:In some clinical settings in which tissue is limited and/or insufficient for molecular testing, physicians may use a cell-free plasma DNA assay to identify EGFR mutations.
- Expert Consensus Opinion 17:Physicians may use cell-free plasma DNA methods to identify EGFR-T790M mutations in lung adenocarcinoma patients with progression or secondary clinical resistance to EGFR-targeted tyrosine kinase inhibitors; if the plasma result is negative, testing of the tumor sample is recommended.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, the increased use of liquid biopsy technology by pathologists and oncologists, more patients benefiting from our assays, liquid biopsy becoming part of standard practice, and our ability to increase adoption of our Target Selector™ platform, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-comments-on-updated-consensus-medical-guidelines-recommending-liquid-biopsy-for-profiling-of-tumor-biomarkers-to-assist-with-the-treatment-of-patients-with-lung-cancer-300590044.html
Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100; or Media Contact: Trevelino/Keller, Colleen Murphy, firstname.lastname@example.org, 404-214-0722, Ext. 109